Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | EBP | Q15125 | 2/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | EBPL | Q9BY08 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623960 | 0.90 | ADRA1D (0.54) | MAPTNPSR1ADRA1DADRA1AADRA1B | |
| SCHEMBL5182997 | 0.87 | ADRA1D (0.61) | ADRA1DADRA1AADRA1BSIGMAR1EBP | |
| SCHEMBL2768860 | 0.86 | ADRA1D (0.61) | MAPTNPSR1ADRA1DADRA1AADRA1B | |
| SCHEMBL6622293 | 0.83 | ADRA1A (0.48) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL2767532 | 0.82 | MAPT (0.66) | MAPTNPSR1HTR1ADRD2SIGMAR1 | |
| SCHEMBL6625036 | 0.81 | LMNA (0.55) | MAPTADRA1AHTR1ADRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27460523 | 0.80 | SIGMAR1 (0.66) | DRD2SIGMAR1EBPTMEM97EBPL | |
| SCHEMBL2766150 | 0.80 | SIGMAR1 (0.72) | MAPTNPSR1ADRA1DADRA1AADRA1B | |
| SCHEMBL5183866 | 0.78 | SIGMAR1 (0.54) | ADRA1DADRA1AADRA1BDRD2SIGMAR1 | |
| SCHEMBL8075010 | 0.78 | SIGMAR1 (0.89) | SIGMAR1EBPTMEM97EBPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | MAPT 4852/4885NPSR1 434/4885ADRA1D 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.